The discovery and development of a new drug can be a lengthy and expensive business (Fig. 1) . The starting point is the active compound as synthesized by the medicinal chemist and screened by the pharmacologist. There then follows a series of complex tests and evaluations to produce a satisfactory formulation and sufficient data for presentation to regulatory authorities such as the Committee on the Safety of Drugs. Unfortunately, this aspect of drug research has been sadly neglected until recent years. Today, however, the formulation of new drugs is based on sound physical and chemical principles.
To illustrate some of the concepts involved I will concentrate on the oral route of administration and pay particular attention to the fate of tablets and capsules after administration ( Fig. 2) . In formulation we can affect the absorption of the drug in two ways: (1) control. In 1939 Berry examined tablet disintegration and suggested that it might be an important factor in availability. ' The fact that the formulation contained the correct quantity of active ingredient was no guarantee of efficacy. Subsequently a disintegration test,was introduced into theBritishPharmacopeia.
This test has been an extremely useful indication of tablet properties but tells one almost nothing about the availability of the drug in solution. Thus one can easily formulate a product that will break up rapidly into its original granules and pass the B.P. test but will give an extremely slow release of the drug. (Table I) . Drug availability can be controlled largely by pharmaceutical factors which the formulator can alter. currently available are weak acids or weak bases. Their total solubility can be altered by adjusting the pH. For example, a weak base will be freely soluble at the low pH of stomach contents, whereas a weak acid will be poorly soluble. To increase the availability of a weak acid in the stomach we must attempt to raise the pH in the immediate environment surrounding the dissolving solid. This will affect Cs and thus the dissolution rate. Two methods are available. Firstly, we can buffer the tablet by adding a solid basic substance to the tablet formulation. A well known example is buffered aspirin (Table III) . Alternatively, and more commonly, we can administer the drug as its sodium salt. Sodium salts of weak where dW/dt is the dissolution rate, S the surface area of the dissolving solid, C the concentration of the drug in the dissolution medium, C5 the concentration of the drug in the diffusion layer surrounding the solid material (saturated solution), and K the dissolution rate constant. Further it has been shown that K=D/L, where D is the diffusion coefficient and L is the thickness of the diffusion layer around the solid material. This equation provides us with a rational approach to formulation. We can alter the variables in the equation to retard release (for example, when sustained release is required) or to increase its rate to give maximum effect in the shortest possible time.
The more interesting factors affecting dissolution rate (Table II) will be discussed below. 
SURFACE AREAS (S)
A reduction in particle size will increase surface area, often giving an increased availability. Examples are sulphadiazine, nitrofurantion, aspirin, and griseofulvin. The last is a striking example, for the amount absorbed increases linearly with the logarithm of the specific surface area (Fig. 3) . Hence, the dosage of the active principle can be reduced without losing efficacy, simply by reducing the particle size.
2-5- acids are freely soluble at low pH as they enhance solubility by producing their own local buffer system. Probably on leaving the immediate environment of the solid the dissolved drug is reprecipitated as the acid form, but in the form of very fine particles. These will dissolve more readily owing to their large surface area. The oral hypoglycaemic agent tolbutamide is a good example of a weakly acidic drug administered as the sodium salt, and hypoglycaemic effect and dissolution rate are both greater for this form (Table IV) .
Several drugs can exist in more than one crystalline form, each with its own thermodynamic stability; the most unstable polymorph is preferred as this will have the most rapid dissolution rate (Table  V) . The optimum polymorphic form can often be prepared by wrong crystalline form, solvated state, or indeed particle size? For example, the crystalline forms of chloramphenicol esters are therapeutically inactive, and only the amorphous form, with small particle size, dissolves rapidly enough in the gastrointestinal tract to be hydrolysed to free absorbable chloramphenicoL' for rapid delivery, provided that the peak in the blood concentration curve did not bring about undesirable side effects. (Fig 5) . Formulation 1 will reach the effective concentration well before formulation 2, but formulation 3 will never reach an effective blood level and thus would be inactive. Formulation 1 has a higher effective blood level concentration than formulation 2, which is maintained for longer. Therefore, this would be the dosage form of choice Therapeutic Non-equivalence of Drugs For any given drug there will often be differences in biological availability and presumably in clinical responses. Such "therapeutic non-equivalence" of dosage forms may be caused by:
(1) Different dosage forms given by the same route, such as capsules, tablets, etc.; (2) the same type of dosage form made by two or more manufacturers; (3) batch to batch variation in a dosage form made by one manufacturer. Normally (2) and (3) will exert a lesser effect on availability than (1) but it is important to realise that one cannot assume that the same dosage forms made by different manufacturers will necessarily give the same therapeutic effect. A muchquoted example of non-equivalence is that by Brice and Hammer," who compared 16 lots of oxytetracycline capsules from 13 different distributors (Fig. 6) . Each of the lots was certified by the Food and Drugs Administration of the United States (F.D.A.), and testing showed that all but one met the standard regulations. However, in vivo studies clearly demonstrated that they were far from equivalent to the branded Pfizer product. After these data were reported the F.D.A.
ruled that capsules from all distributors except Pfizer were no longer eligible for continued certification. Only in a few cases can we make definite suggestions about the causes of differing availability. Thus particle size is known to affect the action of griseofulvin, phenindione, corticosteroids, spironolactone, and tolbutamide; solvation that of ampicillin; physical state that of chloramphenicol; and additives in formulation (excipients) penicillin G and the tetracyclines. Small formulation changes by a Canadian manufacturer of the anticoagulant bishydroxycoumarin led to unexpected clinical problems and a need to adjust the dosage in individual patients."" Hence it cannot be assumed that a drug formulation from one source is therapeutically equivalent to one from another source until this has been proved. It is to be hoped that all manufacturers will provide the medical and pharmaceutical professions with full data on safety and efficacy when marketing a new drug or reformulating an existing product. There is little in official publications on the question of availability.
The pharmaceutical profession is well aware of the problem of biological availability and the effects of formulation. The in vitro dissolution data on oxytetracycline tablets B.P. (Fig. 7) were obtained recently at our University Pharmacy Department by pharmacists from hospitals in the Birmingham region. The rate at which a drug will be absorbed will depend on factors such as the nature of the absorbing tissue, the concentration of the drug, and its ionic character. Most drugs are absorbed by a passive diffusional process that depends on the lipid solubility of the drug (pH-partition hypothesis"3).
That is, the non-ionised neutral molecule will be preferentially h is the membrane thickness. In formulation we can take into account such factors as molecular weight, shape, and solvation which will affect diffusion, as well as the dissociation constant of the drug (pKa) (Fig. 8) , the pH at the absorption site, and the partition coefficient of the unionized form of the drug (Fig. 9) . Acidic drugs will be more lipid-soluble and less water-soluble at low pH, while the reverse will be true at high pH. The converse applies to basic drugs. The environmental pH and drug pKa determine the amount of unionized (absorbable) drug. For an acidic drug (HA) log {HA} = log (A-} + pKa -pH
When pKa=pH, 50% of the drug will be ionized and 50%' will be unionized.
Although the diffusional and partition characteristics of a drug may be altered to increase its absorption, we must bear in mind that any structural modifications may adversely affect the pharmacological response.
In formulation the main contribution of the pharmaceutical scientist is to design a delivery system that gives the optimum quantity of drug in solution at the absorption site, at the correct time. Hence he must consider also the stability of the drug in solution and possible degradation by the fluids of the gastrointestinal tract. Drugs are known to be unstable at the low pH of the stomach as well as at the higher pH values of the intestine and the blood. The former problem can be solved by enteric coating and the latter by administration parenterally or by mouth on a full stomach."' There is no reason to believe that Atromid-S would be helpful in the management of cholecystitis. There is no evidence that serum cholesterol levels are related to bile cholesterol levels or that they are elevated in either cholecystitis or cholelithiasis. Atromid-S does not reduce bile cholesterol levels. Thus cholesterol-lowering agents would not be expected to be of value. There have been many attempts to treat gall stones indirectly, including the administration more recently of cholestyramine,l chenodeoxycholic acid,2 and lecithin.3 HIowever, there is no firm evidence that any of these are effective and there are theoretical arguments to suggest that in the long term they might cause unwanted side effects.
The usual treatment of acute or chronic cholecystitis is surgical. If it is decided to manage the patient medically an antispasmodic and pethidine for relief of pain is advised. Antibiotics such as tetracycline, ampicillin, or rifamide are generally administered, though their efficacy has been questioned4.
Holiday First-aid Box.-Dr. R. G. BULLOCK (Plymouth, Devon) writes: The answer given to the question about the contents of a holiday first-aid box ("Any Questions?" 30 October, p. 294) contains advice that antihistamine cream should be included. Most dermatologists seem to frown on these preparations nowadays,1 as they are potent skin sensitizers. If a specific antihistamine action is needed, as in urticaria, then oral administration is as good. If a simple antipruritic action is wanted then crotamiton (Eurax) ointment or lotion is just as effective (or ineffective). Dr. J. N. ROSENBERG (New Cross Hospital, London S.E.14)
writes: I was surprised to see an antihistamine cream included in the holiday first-aid box. The incidence of skin sensitization following topical antihistamines has been put between 5 and 8-8%.2 Other well known hazards are photosensitivity and cross sensitivity reactions which may be produced by promethazine and phenothiazines respectively.3 OUR EXPERT replies: The comments on the antihistamine cream are welcomed. Skin sensitization is certainly a danger with repeated and continuing application but surely the risk would be minimal in the casual first-aid application to insect or jelly fish stings, for which it is very effective.
